FDA clears Roche's automated D-Dimer test:
This article was originally published in Clinica
Roche Diagnostics has received US FDA 510(k) marketing clearance to use its D-Dimer assay, for excluding a diagnosis of deep vein thrombosis (DVT) and pulmonary embolism, on an automated clinical chemistry platform. The assay can be run on the firm's Roche/Hitachi and Cobas Integra chemistry analysers and can produce a result in just 10 minutes. DVT affects around 1 million people in the US each year.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.